Home›Trial›NCT06563414
NCT06563414RECRUITING

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Study Summary

This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).

Conditions
Epidermolysis Bullosa DystrophicaEpidermolysis Bullosa Dystrophica, RecessiveEpidermolysis Bullosa Dystrophica Dominans
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
KRYS
Krystal Biotech
Gene Therapy
F29/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549391+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 40 participants
Sponsor Catalyst Profile

Krystal Biotech (KRYS) is the sponsoring company for this trial. BiotechSign currently grades this company F (29/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

KRYS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.